Search

First CMML guidelines produced by EHA, now available

Chronic myelomonocytic leukemia (CMML) is a rare disease with overlapping features of two categories of bone marrow and blood cell disorders that poses challenges in clinical management.

Read more

‘Rare Cancers in all EU policies’: Prof Elizabeth Macintyre expresses strong EHA support for the Rare Cancers Europe agenda

On September 28, EHA President Elizabeth Macintyre addressed an audience that included Members of the European Parliament, and officials of the European Commission and the European Medicines Agency, as well as members of the Rare Cancers Europe (RCE) partnership.

Read more

EHA-SWG Scientific Meeting on Patient-centered Geriatric Hematology - report

Live sessions: October 6-7, 2021

Chairs: Prof R Cordoba (Spain) and Dr V Goede (Germany)

An international group of hematologists, specialist nurses, patient advocates, geriatricians, basic research, and pharma representatives gathered digitally to participate in this meeting.

Read more

EHA Lymphoma Group

The EHA Lymphoma Group (EHA LyG) is a specialized working group that was established in 2014.

Read more

Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an open-label, dose escalation followed by open-label extension in a single-arm phase I/II study

Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.

Read more

Position of EHA on Clinical Trials

 

The challenge
In Europe, the number of clinical trials is steadily decreasing. From 2007 to 2010, their number has decreased by some 20 percent from 5,028 to 4,193.

Read more

EHA and EMBL-EBI are launching CBTH

The Hague, May 2022 - The European Hematology Association (EHA) and the EMBL’s European Bioinformatics Institute (EMBL-EBI) are launching a new mentoring program, Computational Biology Training in Hematology (CBTH), this June.

Read more